BioWorld Asia

Aug. 14, 2002

Peptor's DiaPep277 Diabetes Product Licensed By Aventis

JERUSALEM, Israel - Peptor Ltd. said July 30 it signed a worldwide agreement with Aventis SA, granting it exclusive rights to develop and commercialize Peptor's DiaPep277 drug for the treatment of autoimmune diabetes. (BioWorld International) Read More

British Biotech Collaborates With GeneSoft In Anti-Infectives Deal

Cureon Raises DKK34M For Antisense DNA Analogue

Evolutec Raises £1.8 Million In Third Round Of Financing

Compugen Uploads Gencarta Database, Extends Pfizer Deal

Other News To Note

Phico Raises £450,000 To Begin Antibiotic Development

Start-Up NascaCell's Platform Speeding Drug Discovery

Pharmos To Study Dexanabinol In Impairment Following Surgery

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...